Cargando…

Endoscopic submucosal dissection for early esophagogastric junction adenocarcinomas: a systematic review

BACKGROUND: Esophagogastric junction adenocarcinomas (EGJAs) include esophageal and gastric cardia adenocarcinomas (GCAs). These tumors are currently regarded as a single entity, with similar surgical and oncological therapies, although they originate from different organs. Endoscopy allows an early...

Descripción completa

Detalles Bibliográficos
Autores principales: Doumbe-Mandengue, Paul, Pellat, Anna, Terris, Benoit, Beuvon, Frédéric, Leconte, Mahaut, Dohan, Anthony, Chaussade, Stanislas, Coriat, Romain, Barret, Maximilien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210784/
https://www.ncbi.nlm.nih.gov/pubmed/35784626
http://dx.doi.org/10.20524/aog.2022.0719
_version_ 1784730229036548096
author Doumbe-Mandengue, Paul
Pellat, Anna
Terris, Benoit
Beuvon, Frédéric
Leconte, Mahaut
Dohan, Anthony
Chaussade, Stanislas
Coriat, Romain
Barret, Maximilien
author_facet Doumbe-Mandengue, Paul
Pellat, Anna
Terris, Benoit
Beuvon, Frédéric
Leconte, Mahaut
Dohan, Anthony
Chaussade, Stanislas
Coriat, Romain
Barret, Maximilien
author_sort Doumbe-Mandengue, Paul
collection PubMed
description BACKGROUND: Esophagogastric junction adenocarcinomas (EGJAs) include esophageal and gastric cardia adenocarcinomas (GCAs). These tumors are currently regarded as a single entity, with similar surgical and oncological therapies, although they originate from different organs. Endoscopy allows an early-stage diagnosis, where both subtypes can be differentiated. With this review we aimed to describe the outcomes of endoscopic submucosal dissection for the treatment of esophageal adenocarcinomas (EAs) and GCAs. METHODS: We identified studies by screening PubMed, Embase and Web of Science. We included all 19 studies that mentioned at least one of the following criteria of interest: en bloc; R0 resection; local recurrences; and/or overall survival. RESULTS: We found an en bloc resection rate superior to 90% for both tumors. R0 resections rates were over 60% for most EAs, vs. 83% for most GCAs. We recorded less than 13% and 20% early and late adverse events for EA, and 10% and 7% for GCA. The local recurrence rate was 8% for EA and 3% for GCA. The overall survival was over 90%. CONCLUSIONS: Endoscopic submucosal dissection is safe and effective for esophageal and GCAs. These data support the extension of the use of endoscopic submucosal dissection to all EGJAs, including early EAs.
format Online
Article
Text
id pubmed-9210784
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hellenic Society of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-92107842022-07-01 Endoscopic submucosal dissection for early esophagogastric junction adenocarcinomas: a systematic review Doumbe-Mandengue, Paul Pellat, Anna Terris, Benoit Beuvon, Frédéric Leconte, Mahaut Dohan, Anthony Chaussade, Stanislas Coriat, Romain Barret, Maximilien Ann Gastroenterol Original Article BACKGROUND: Esophagogastric junction adenocarcinomas (EGJAs) include esophageal and gastric cardia adenocarcinomas (GCAs). These tumors are currently regarded as a single entity, with similar surgical and oncological therapies, although they originate from different organs. Endoscopy allows an early-stage diagnosis, where both subtypes can be differentiated. With this review we aimed to describe the outcomes of endoscopic submucosal dissection for the treatment of esophageal adenocarcinomas (EAs) and GCAs. METHODS: We identified studies by screening PubMed, Embase and Web of Science. We included all 19 studies that mentioned at least one of the following criteria of interest: en bloc; R0 resection; local recurrences; and/or overall survival. RESULTS: We found an en bloc resection rate superior to 90% for both tumors. R0 resections rates were over 60% for most EAs, vs. 83% for most GCAs. We recorded less than 13% and 20% early and late adverse events for EA, and 10% and 7% for GCA. The local recurrence rate was 8% for EA and 3% for GCA. The overall survival was over 90%. CONCLUSIONS: Endoscopic submucosal dissection is safe and effective for esophageal and GCAs. These data support the extension of the use of endoscopic submucosal dissection to all EGJAs, including early EAs. Hellenic Society of Gastroenterology 2022 2022-05-12 /pmc/articles/PMC9210784/ /pubmed/35784626 http://dx.doi.org/10.20524/aog.2022.0719 Text en Copyright: © Hellenic Society of Gastroenterology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Doumbe-Mandengue, Paul
Pellat, Anna
Terris, Benoit
Beuvon, Frédéric
Leconte, Mahaut
Dohan, Anthony
Chaussade, Stanislas
Coriat, Romain
Barret, Maximilien
Endoscopic submucosal dissection for early esophagogastric junction adenocarcinomas: a systematic review
title Endoscopic submucosal dissection for early esophagogastric junction adenocarcinomas: a systematic review
title_full Endoscopic submucosal dissection for early esophagogastric junction adenocarcinomas: a systematic review
title_fullStr Endoscopic submucosal dissection for early esophagogastric junction adenocarcinomas: a systematic review
title_full_unstemmed Endoscopic submucosal dissection for early esophagogastric junction adenocarcinomas: a systematic review
title_short Endoscopic submucosal dissection for early esophagogastric junction adenocarcinomas: a systematic review
title_sort endoscopic submucosal dissection for early esophagogastric junction adenocarcinomas: a systematic review
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210784/
https://www.ncbi.nlm.nih.gov/pubmed/35784626
http://dx.doi.org/10.20524/aog.2022.0719
work_keys_str_mv AT doumbemandenguepaul endoscopicsubmucosaldissectionforearlyesophagogastricjunctionadenocarcinomasasystematicreview
AT pellatanna endoscopicsubmucosaldissectionforearlyesophagogastricjunctionadenocarcinomasasystematicreview
AT terrisbenoit endoscopicsubmucosaldissectionforearlyesophagogastricjunctionadenocarcinomasasystematicreview
AT beuvonfrederic endoscopicsubmucosaldissectionforearlyesophagogastricjunctionadenocarcinomasasystematicreview
AT lecontemahaut endoscopicsubmucosaldissectionforearlyesophagogastricjunctionadenocarcinomasasystematicreview
AT dohananthony endoscopicsubmucosaldissectionforearlyesophagogastricjunctionadenocarcinomasasystematicreview
AT chaussadestanislas endoscopicsubmucosaldissectionforearlyesophagogastricjunctionadenocarcinomasasystematicreview
AT coriatromain endoscopicsubmucosaldissectionforearlyesophagogastricjunctionadenocarcinomasasystematicreview
AT barretmaximilien endoscopicsubmucosaldissectionforearlyesophagogastricjunctionadenocarcinomasasystematicreview